The treatment for hepatitis C virus (HCV) has dramatically changed with the introduction of direct-acting antivirals (DAAs). The efficacy and safety of interferon-free therapy before and after liver transplantation have been recently confirmed, beginning a new era in the strategy for treating HCV in transplant recipients. Establishment of treatment strategy for HCV in nonliver solid organ transplantation is currently in progress. Yet there are some minor unresolved issues, such as drug-drug interactions, treatment for decompensated cirrhosis, and treatment for renal failure. These problems are expected to be solved in the near future, and the poor prognosis of HCV-positive transplant recipients will improve.
展开▼
